# Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

> **NCT00061633** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 169 (actual)

## Conditions studied

- Infections, Gram-Positive Bacterial
- Abscess
- Burns
- Cellulitis
- Ulcer
- Wound Infections

## Interventions

- **DRUG:** Telavancin
- **DRUG:** Vancomycin or antistaphylococcal penicillin

## Key facts

- **NCT ID:** NCT00061633
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061633, "Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00061633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*